Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.64 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | HTR7 | P34969 | 6/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29111661 | 1.00 | UBE2T (0.64) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL11437569 | 1.00 | UBE2T (0.64) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL4700806 | 1.00 | UBE2T (0.64) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL8088124 | 0.98 | UBE2T (0.66) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL10763327 | 0.93 | UBE2T (0.68) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL27509034 | 0.91 | SMN1; SMN2 (0.68) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| Bromide SCHEMBL11522514 | 0.90 | SMN1; SMN2 (0.66) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL3529770 | 0.86 | UBE2T (0.72) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL9641726 | 0.86 | SMN1; SMN2 (0.70) | UBE2TASIC3ALOX15HTTSMN1; SMN2 | |
| SCHEMBL28125052 | 0.84 | UBE2T (0.61) | UBE2TASIC3ALOX15HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | claimed |
| US-4026815-A | ADDING A PHOSPHONOCARBOXYLIC ACID AND A BENZIMIDAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | claimed |
| US-4000079-A | ANTIFREEZE ADDITIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7384966-B2 | 2-arylbenzothiazole derivatives | PHARMINXO LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-0949238-A1 | SUBSTITUTED PROPIONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0854388-A2 | Negative-type image recording materials | FUJI PHOTO FILM CO., LTD. (JP) | 1998-07-22 | — | — | EP | disclosed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | disclosed |
| US-4235838-A | IN OIL AND GAS WELLS | PETROLITE CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
| US-4026815-A | ADDING A PHOSPHONOCARBOXYLIC ACID AND A BENZIMIDAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
| US-4000079-A | ANTIFREEZE ADDITIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3972890-A | ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | UBE2T 4197/4885ASIC3 3291/4885ALOX15 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.